Kellogg Co. (K): https://www.nydailynews.com/news/nationa...

Play Episode

4min

Proactive - Interviews for investors

Opioid-Free pain relief: AFT’s global expansion strategy

AFT Pharmaceuticals Ltd Managing Director Dr Hartley Atkinson talked with Proactive at the AIM's Small and Midcap Conference about the company's unique approach to drug development, its expanding global footprint, and what lies ahead in 2025. AFT Pharmaceuticals is focused on creating pharmaceuticals "with a difference," targeting unmet needs and reducing reliance on opioids. “We don’t sell anything we don’t believe in,” said Dr Atkinson, highlighting the importance of alternatives to opioid treatments. One of the company’s key analgesic products helps avoid opioid use — a particularly timely innovation in light of the global opioid crisis. Dr Atkinson discussed the company’s core markets, with a strong presence in New Zealand and Australia, generating approximately 150 million in revenue. AFT also maintains operations in Asia and now exports to around 80 countries. The company has experienced sustained growth, having quadrupled in size over the past decade and doubled in the last five years. AFT has established six new affiliates across regions including Singapore, Hong Kong, South Africa, Canada, the UK, and Europe. Looking ahead, the company plans several product launches across Australia and New Zealand and anticipates five drug launches in China — the world’s second-largest pharmaceutical market. “For us, that’s going to be an interesting journey,” Atkinson added. #AFTPharmaceuticals #OpioidAlternatives #PharmaceuticalInnovation #ChinaPharma #DrugDevelopment #HealthcareGrowth #ASXStocks #BiotechInvesting #GlobalHealthcare #PharmaExpansion

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

Light Science Technologies CEO on Injecta Fire Barrier solution to UK's unsafe cladding dilemma

Light Science Technologies Holdings PLC (AIM:LST) CEO Simon Deacon talked with Proactive's Stephen Gunnion about the significant opportunity surrounding the company’s Injecta Fire Barrier solution, particularly in light of ongoing fire safety issues in the UK’s residential building sector. Deacon highlighted that the UK still has more than 33,000 buildings between 11m and 18m in height, and over 11,000 high-risk buildings above 18m, that require urgent fire protection measures. He referenced a government estimate suggesting a potential £22 billion cost to address the cladding crisis, which has persisted since the Grenfell tragedy. The Injecta Fire Barrier, acquired in late 2023, offers what Deacon described as a "unique solution"—one that avoids facade removal by injecting fire-resistant material directly into cavities, providing over two hours of fire resistance. He said, "We're three times less in cost and much quicker to install than traditional methods." He noted the division secured £2.7 million in orders during 2024, performing strongly and receiving positive feedback for its efficiency and clean delivery. With an average order value over £500,000 and significant market scope, Deacon framed the opportunity as a scalable revenue driver for the group. The company is targeting £50 million in revenue over the next five years, with Injecta Fire Barrier expected to be a key growth driver. 👉 For more updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #FireSafety #BuildingSafety #InjectaFireBarrier #LightScienceTechnologies #GrenfellLegacy #PropertyInvestment #ConstructionInnovation #FireProtection #CladdingCrisis #UKHousingSafety #ProactiveInvestors #SimonDeacon #BuildingRegulations #RealEstateSafety #PassiveFireProtection

Proactive - Interviews for investors

Newmark Security CEO on growth drivers, expanding D2E model globally

Newmark Security PLC CEO Marie-Claire Dwek talked with Proactive's Stephen Gunnion about the company’s latest trading update, which highlighted stronger revenue performance in the second half of the financial year. Dwek said the growth was primarily driven by the Human Capital Management (HCM) division, especially in North America, where both hardware and service-related sales have increased. She explained, “The more clocks we sell, the more recurring revenue we sell, the more services we sell.” This growth model is being further supported by a Direct to End user approach, with active integrations already in place with Oracle and Workday, and further development underway with SAP. Dwek also spoke about their efforts to diversify, including moves into lower-cost market segments, which are typically dominated by Chinese manufacturers. This allows Newmark to capture new customer groups while maintaining service-based revenue opportunities. Outside North America, Newmark continues to see growth in Europe, citing customers like Marks & Spencer and Protime. The company is also building pipeline opportunities in collaboration with Oracle and is working on exclusivity in North America with one partner. Dwek described this as “a whole new market for us that was previously untapped.” For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content. #NewmarkSecurity #MarieClaireDwek #HCM #EnterpriseSoftware #RecurringRevenue #OracleIntegration #Workday #SAPIntegration #WorkforceManagement #TechGrowth #NorthAmericaExpansion #SecuritySolutions #HumanCapitalManagement #ProactiveInvestors #D2EModel

Followers	36
Posts	3353
Boards Moderated	1
Alias Born	11/13/2013

Volume:	1,461,110
Day Range:	82.355 - 82.65
Bid:
Ask:
Last Trade Time:	3:38:12 PM EDT
Total Trades:	16,106

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

K Detailed Quote

Recent K News

More K News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent K News

Go Ad-Free